Live unlimited

Sickle cell disease (SCD) is a group of rare genetic blood disorders affecting millions of people worldwide. It is a debilitating and life-threatening haematological condition caused by misshapen red blood cells, that severely impacts the life of those affected and their caregivers.

At Novo Nordisk we’re dedicated to collaborating with the sickle cell disease community to address the challenges encountered by individuals living with Sickle Cell Disease (SCD) across the spectrum of care – from improving clinical outcomes to dismantling stigmas.

We’re committed to developing and commercialising innovative treatments for those living with sickle cell disease and other rare blood, endocrine, and renal disorders. We believe that a comprehensive understanding of the challenges faced by people living with sickle cell disease will help improve screening, support programmes, services, and policies to help relieve the burden of the disease. Everyone has the right to good health and care tailored to their needs, no matter how rare their condition may be.

The neglect of sickle cell disease as a rare disorder has led to limited efforts in finding a cure and improving therapy, resulting in significant unmet treatment needs. We have to target the underlying disease as well as the acute symptoms.

This is our ambition: to provide patients and physicians with a portfolio of medicines tailored to address individual needs.

We have 8 marketed products in our portfolio within rare blood and endocrine disorders, with more products currently in clinical trials to help address the unmet need in treatment for people living with sickle cell disease (see programme below).

We have R&D centres in China, Denmark, India, UK and the US and production sites in Denmark, Brazil, China, France and the US that support our ambitions of building a portfolio of solutions for sickle cell disease.

For people living with a rare disease, the lack of awareness and treatment options can make the entire experience extremely challenging and uncertain. Though each rare disease is complex and challenging to diagnose and manage, they do share many commonalities.

World Health Organization, African Region. Key facts; https://www.afro.who.int/health-topics/sickle-cell-disease. Last accessed November 2024.

The Lancet Global Health. “The landscape for rare diseases in 2024.” The Lancet. Global health vol. 12,3 (2024): e341

Rare Disease Day, Frequently asked questions. Available at: https://rarediseases.org/wp-content/uploads/2019/01/RDD-FAQ-2019.pdf

FOR HEALTHCARE PROFESSIONALS ONLY

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.

HQ24SCD00003 November 2024

Novo Nordisk Healthcare AG, Zurich, Switzerland

For healthcare professionals only